RET (Phospho-Y981) polyclonal antibody

Product Specifications

Background

The Ret gene products include two glycosylated proteins and, in tunicamycin treated cells, a non-glycosylated protein consistent with the predicted Ret molecular weight based on sequence analysis. Tumor-specific rearrangements of the Ret proto-oncogene have been identified in papillary thyroid carcinomas leading to the formation of different transforming fusion proteins sharing the tyrosine kinase domain of Ret. In contrast to the Ret proto-oncogene, the rearranged forms are constitutively phosphorylated on tyrosine and are translocated from the membrane to the cytoplasm.

CAS Number

9007-83-4

Structure Composition

Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Product Name Alternative

Proto-oncogene tyrosine-protein kinase receptor Ret; Cadherin family member 12; Proto-oncogene c-Ret; RET; CDHF12; CDHR16; PTC; RET51

Swiss Prot

P07949

Reactivity

Human, Mouse, Rat

Immunogen

Synthetic phosphopeptide derived from human RET around the phosphorylation site of Tyrosine 981.

Conjugation

Unconjugated

Applications

Dilution

WB:1:500~1:1000

Purity

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .